AKT1 and prostate cancer: However, we provided evidence that inhibition of de novo protein synthesis by CHX failed to have overt effect on class I/II HDACI‐induced suppression of AKT phosphorylation in prostate cancer cells and the drug effect appears to be an immediate event (30 min post‐treatment).